Vickram Ramkumar
YOU?
Author Swipe
View article: Cochlear Amyloid-β42 Accumulation Drives Progressive Auditory Neuropathy in 5XFAD Mice: A Potential Biomarker for Early Alzheimer's Disease
Cochlear Amyloid-β42 Accumulation Drives Progressive Auditory Neuropathy in 5XFAD Mice: A Potential Biomarker for Early Alzheimer's Disease Open
Background Emerging evidence suggests auditory dysfunction may serve as an early biomarker of Alzheimer’s disease (AD). This study investigates amyloid-beta 42 (Aβ42) accumulation in the cochlea and its relationship to auditory dysfunction…
View article: Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation
Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation Open
Cisplatin is a chemotherapy drug used to treat different solid tumors, including ovarian, bladder, lung, and head and neck cancers. One of its significant side effects is ototoxicity, especially when high doses are required. Cisplatin-indu…
View article: Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity
Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity Open
Cisplatin is chemotherapy used for solid tumor treatment like lung, bladder, head and neck, ovarian and testicular cancers. However, cisplatin-induced ototoxicity limits the utility of this agent in cancer patients, especially when dose es…
View article: Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity
Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity Open
Hearing loss is a significant health problem that can result from a variety of exogenous insults that generate oxidative stress and inflammation. This can produce cellular damage and impairment of hearing. Radiation damage, ageing, damage …
View article: Transient Receptor Potential Channels and Auditory Functions
Transient Receptor Potential Channels and Auditory Functions Open
Significance: Transient receptor potential (TRP) channels are cation-gated channels that serve as detectors of various sensory modalities, such as pain, heat, cold, and taste. These channels are expressed in the inner ear, suggesting that …
View article: Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss
Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss Open
Regulators of G protein signaling (RGS) accelerate the GTPase activity of G proteins to enable rapid termination of the signals triggered by G protein-coupled receptors (GPCRs). Activation of several GPCRs, including cannabinoid receptor 2…
View article: Ototoxicity of Non-aminoglycoside Antibiotics
Ototoxicity of Non-aminoglycoside Antibiotics Open
It is well-known that aminoglycoside antibiotics can cause significant hearing loss and vestibular deficits that have been described in animal studies and in clinical reports. The purpose of this review is to summarize relevant preclinical…
View article: Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity
Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity Open
Numerous potential protective agents show promise in animal models by systemic or local administration. However, clinical trials have not shown much efficacy to date with the exception of sodium thiosulfate. There is an urgent need to disc…
View article: Targeting Inflammatory Processes Mediated by TRPVI and TNF-α for Treating Noise-Induced Hearing Loss
Targeting Inflammatory Processes Mediated by TRPVI and TNF-α for Treating Noise-Induced Hearing Loss Open
Noise trauma is the most common cause of hearing loss in adults. There are no known FDA approved drugs for prevention or rescue of noise-induced hearing loss (NIHL). In this study, we provide evidence that implicates stress signaling molec…
View article: Local Drug Delivery for Prevention of Hearing Loss
Local Drug Delivery for Prevention of Hearing Loss Open
Systemic delivery of therapeutics for targeting the cochlea to prevent or treat hearing loss is challenging. Systemic drugs have to cross the blood-labyrinth barrier (BLB). BLB can significantly prevent effective penetration of drugs in ap…
View article: Mechanisms of Cisplatin-Induced Ototoxicity and Prevention
Mechanisms of Cisplatin-Induced Ototoxicity and Prevention Open
Cisplatin is a highly effective antineoplastic agent used to treat solid tumors. Unfortunately, the administration of this drug leads to significant side effects, including ototoxicity, nephrotoxicity, and neurotoxicity. This review addres…
View article: The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss
The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing Loss Open
Previous studies have demonstrated the presence of cannabinoid 2 receptor (CB2R) in the rat cochlea which was induced by cisplatin. In an organ of Corti-derived cell culture model, it was also shown that an agonist of the CB2R protected th…
View article: Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection Open
Evidence of significant hearing loss during the early days of use of cisplatin as a chemotherapeutic agent in cancer patients has stimulated research into the causes and treatment of this side effect. It has generally been accepted that he…
View article: Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity
Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity Open
Cisplatin-induced ototoxicity is one of the major factors limiting cisplatin chemotherapy. Ototoxicity results from damage to outer hair cells (OHCs) and other regions of the cochlea. At the cellular level, cisplatin increases reactive oxy…
View article: Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol
Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol Open
Prostate cancer (PCa) is the second leading cause of cancer deaths in men. A better understanding of the molecular basis of prostate cancer proliferation and metastasis should enable development of more effective treatments. In this study …
View article: Adenosine A<sub>1</sub>Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea
Adenosine A<sub>1</sub>Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea Open
Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is mediated in part by increasing levels of reactive oxygen species (ROS) via the NOX3 NADPH oxidase pathway in the cochlea. Recent studies implicate ROS gene…